Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Table 2
Baseline characteristics.
TJ-54 (n = 48)
Placebo (n = 50)
Test statics
Age (years)
46.4 ± 9.7
5.4 ± 9.6
ns
Gender (males/females)
28/20
32/18
ns
Duration of disease (years)
23.7 ± 10.4
22.5 ± 9.6
ns
Duration of treatment (years)
3.2 ± 10.5
21.0 ± 10.3
ns
CPZ equivalents (mg)
1905.8 ± 1541.5
1941.8 ± 1948.1
ns
Type
Paranoid
39
35
Catatonic
6
5
Undifferentiated
3
10
ns
PANSS (total)
113.0 ± 23.0
111.1 ± 21.1
ns
PANSS (positive)
28.6 ± 5.4
28.7 ± 6.0
ns
PANSS (negative)
27.9 ± 7.1
27.8 ± 7.3
ns
PANSS (general)
56.6 ± 13.3
54.6 ± 11.9
ns
CGI-S
5.4 ± 0.8
5.5 ± 0.8
ns
GAF
27.4 ± 7.5
27.2 ± 6.4
ns
DIEPSS
4.3 ± 4.0
4.8 ± 4.5
ns
CPZ: chlorpromazine; PANSS: Positive and Negative Syndrome Scale; CGI-S: Clinical Global Impression-Severity; GAF: Global Assessment of Functioning; DIEPSS: Drug Induced Extrapyramidal Symptoms Scale.
